



(51) International Patent Classification:

A61K 31/455 (2006.01) C07D 213/80 (2006.01)
A61K 31/7024 (2006.01)

(21) International Application Number:

PCT/US2023/063565

(22) International Filing Date:

02 March 2023 (02.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/315,640 02 March 2022 (02.03.2022) US

(71) Applicant: MITOPOWER, INC. [US/US]; 2671 Marshall Drive, Palo Alto, California 94303 (US).

(72) Inventors: SUBRAMANIAN, G. Mani; 15421 Vista Serena, Los Altos Hills, California 94022 (US). GANAPATI, Gangadhara; 2671 Marshall Drive, Palo Alto, California 94303 (US). DESAI, Manoj Chandrasinhji; 854 Carter Acres Lane, Martinez, California 94553 (US).

ZACHARIAH, Nikhil Saji; B-317, Sobha-Coral, Sobha Suburbia, Jakkur, Karnataka, Bangalore 560055 (IN). KUMARKS, Ajay; #322, 19th cross, 3rd main road, 6th block, Jayanagar, Karnataka, Bangalore 560070 (IN). PRANESH, Gautham Tumkur; 5023, Prestige Wellington Park, Karnataka, Bangalore 560013 (IN).

(74) Agent: SINGH, Sunil; 3001 West Big Beaver Rd., Suite 624, Troy, Michigan 48084 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: NOVEL PRODRUGS DERIVED FROM NICOTINIC ACID AND RIBOSE




Fig. 1

Fig. 1

(57) Abstract: Disclosed are novel prodrugs derived from nicotinic acid and pharmaceutical compositions thereof which may be used to treat or prevent a variety of medical disorders, which may be characterized by mitochondrial dysfunction. The compounds and pharmaceutical compositions thereof may be used to treat or prevent metabolic disorders, cardiovascular disorders, cerebrovascular disorders, liver disorders, a kidney disorders or muscle disorders.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

28 December 2023 (28.12.2023)